Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > NUCRYST Pharmaceuticals begins Phase 2 clinical trial

December 4th, 2003

NUCRYST Pharmaceuticals begins Phase 2 clinical trial

Abstract:
NUCRYST Pharmaceuticals Corp., a subsidiary of The Westaim Corporation, today announced that it has
begun its first Phase 2 human clinical trial of a topical cream formulation of its nanocrystalline silver. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and other skin conditions and represents a biological application of nanotechnology.

Source:
PRNewswire

Bookmark:

Related News Press

Nanomedicine

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013